Abdulkadir Çat
Research Subjects
Abdulkadir Çat has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Kamil Taha Uçar
Department of Medical Biochemistry, University of Health Sciences , Basaksehir Cam and Sakura City Hospital , Istanbul , Türkiye
3 shared publications Kamil Taha Uçar
Bilecik Halk Sağlığı Laboratuvarı
2 shared publicationsAlper Gümüş
Istanbul Gaziosmanpasa Training and Research Hospital, Medical Biochemistry, Istanbul, Turkey
1 shared publication- Alper Gümüş
Affiliations Medical Biochemistry Laboratory, Çam Sakura City Hospital, University of Health Sciences, Istanbul, Turkey, Institute of Health Sciences, Istanbul University, Istanbul, Turkey
1 shared publication - Betül Evran
Department of Medical Biochemistry, Health Science University, Istanbul Basaksehir Cam and Sakura City Hospital
1 shared publication - Cihan Coşkun
Biochemistry Department , University of Health Sciences, Başakşehir Çam and Sakura City Hospital , İstanbul , Türkiye
1 shared publication
Latest Publications
- 2 January 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 85 (1) , 11-19
Glucometer versus analyzer: comparable results with negligible clinical risk
This study assessed the reliability of Roche Accu-Chek Inform II glucometers in a real-world setting. A retrospective analysis was conducted on 6,695 paired results. Capillary samples were tested using Roche Accu-Chek Inform II glucometers, while venous samples were analyzed using Roche Cobas c503/702 analyzers. Compliance was assessed using modified criteria based on the ISO 15197 guideline and the CLSI EP09-A3 guideline using Passing-Bablok regression analysis, Bland-Altman plots, and Surveillance Error Grid (SEG) analysis. The overall compliance of glucometer results within +/- 15% or 0.83 mmol/L (15 mg/dL) of the reference method was 81.5%, below the acceptance criterion of 94.6%. SEG analysis showed that 90.3% of the paired results fell within the No-risk zone, with less than 0.001% in the moderate/lower-risk zone. The Emergency Department results indicated 87.8% overall compliance and 92.2% of pairs falling in the No-risk zone. Based on the regression analysis, the glucometer results showed a positive constant bias of nearly 0.33 mmol/L (6 mg/dL). The Bland-Altman plots showed a positive mean difference of 0.43 mmol/L for results <= 5.55 mmol/L (<= 100 mg/dL) and a positive mean percentage difference of 3.77% for results >5.55 mmol/L (>100 mg/dL), within the permissible deviation. The compliance values ranged from 76.0% to 90.3% for clinical concentration groups, with the highest compliance found between >16.65-22.20 mmol/L (>300-400 mg/dL). The Accu-Chek Inform II glucometers demonstrated in real-world reliability, with most results falling within acceptable risk categories. However, compliance still needs improvement, so manufacturers should assess opportunities for advancement.
- 2 January 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 85 (1) , 11-19
Glucometer versus analyzer: comparable results with negligible clinical risk
This study assessed the reliability of Roche Accu-Chek Inform II glucometers in a real-world setting. A retrospective analysis was conducted on 6,695 paired results. Capillary samples were tested using Roche Accu-Chek Inform II glucometers, while venous samples were analyzed using Roche Cobas c503/702 analyzers. Compliance was assessed using modified criteria based on the ISO 15197 guideline and the CLSI EP09-A3 guideline using Passing-Bablok regression analysis, Bland-Altman plots, and Surveillance Error Grid (SEG) analysis. The overall compliance of glucometer results within +/- 15% or 0.83 mmol/L (15 mg/dL) of the reference method was 81.5%, below the acceptance criterion of 94.6%. SEG analysis showed that 90.3% of the paired results fell within the No-risk zone, with less than 0.001% in the moderate/lower-risk zone. The Emergency Department results indicated 87.8% overall compliance and 92.2% of pairs falling in the No-risk zone. Based on the regression analysis, the glucometer results showed a positive constant bias of nearly 0.33 mmol/L (6 mg/dL). The Bland-Altman plots showed a positive mean difference of 0.43 mmol/L for results <= 5.55 mmol/L (<= 100 mg/dL) and a positive mean percentage difference of 3.77% for results >5.55 mmol/L (>100 mg/dL), within the permissible deviation. The compliance values ranged from 76.0% to 90.3% for clinical concentration groups, with the highest compliance found between >16.65-22.20 mmol/L (>300-400 mg/dL). The Accu-Chek Inform II glucometers demonstrated in real-world reliability, with most results falling within acceptable risk categories. However, compliance still needs improvement, so manufacturers should assess opportunities for advancement.
- 2 May 2024
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 84 (3) , 147-153
Measurement uncertainty in clinical chemistry: ISO 20914 versus nordtest or intermediate precision versus bias
Measuring uncertainty (MU) is crucial to ensure the accuracy and precision of laboratory results. This study compares the ISO 20914 and Nordtest guidelines to analyze the MU values for 20 clinical chemistry analytes over six months. The researchers calculated MU components, including within-laboratory reproducibility (Rw), laboratory analytical performance bias (u(bias)), and combined standard uncertainty (uc), based on internal quality control and external quality assessment data. The final expanded uncertainty (U) values were determined by multiplying the combined uncertainty with a coverage factor (k = 2 for 95% Confidence Interval), following each guideline's respective procedures. Clinical chemistry analytes were analyzed on Roche Cobas 6000 c501 auto analyzer (Roche Diagnostics, Mannheim, Germany) and manufacturer's kits were used analysis. The results show that 11 out of 20 clinical chemistry analytes met the targeted maximum allowable measurement uncertainty (MAU) values when calculated according to ISO 20914 guideline. Also, 11 out of 20 clinical chemistry analytes' MU values met the MAU values with the Nordtest guideline's recommended calculations. However, some tests met the MAU in the ISO 20914 approach but not in the Nordtest guideline, and vice versa. The study found that intermediate precision (uRw) in the ISO 20914 approach and performance bias (u(bias)) in the Nordtest approach significantly impacted MU values. The research highlights the importance of standardization in MU calculation approaches across clinical laboratories. These findings have implications for patient care and clinical decision-making, emphasizing the importance of selecting appropriate laboratory guidelines for routine use.
- 2 May 2024
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 84 (3) , 147-153
Measurement uncertainty in clinical chemistry: ISO 20914 versus nordtest or intermediate precision versus bias
Measuring uncertainty (MU) is crucial to ensure the accuracy and precision of laboratory results. This study compares the ISO 20914 and Nordtest guidelines to analyze the MU values for 20 clinical chemistry analytes over six months. The researchers calculated MU components, including within-laboratory reproducibility (Rw), laboratory analytical performance bias (u(bias)), and combined standard uncertainty (uc), based on internal quality control and external quality assessment data. The final expanded uncertainty (U) values were determined by multiplying the combined uncertainty with a coverage factor (k = 2 for 95% Confidence Interval), following each guideline's respective procedures. Clinical chemistry analytes were analyzed on Roche Cobas 6000 c501 auto analyzer (Roche Diagnostics, Mannheim, Germany) and manufacturer's kits were used analysis. The results show that 11 out of 20 clinical chemistry analytes met the targeted maximum allowable measurement uncertainty (MAU) values when calculated according to ISO 20914 guideline. Also, 11 out of 20 clinical chemistry analytes' MU values met the MAU values with the Nordtest guideline's recommended calculations. However, some tests met the MAU in the ISO 20914 approach but not in the Nordtest guideline, and vice versa. The study found that intermediate precision (uRw) in the ISO 20914 approach and performance bias (u(bias)) in the Nordtest approach significantly impacted MU values. The research highlights the importance of standardization in MU calculation approaches across clinical laboratories. These findings have implications for patient care and clinical decision-making, emphasizing the importance of selecting appropriate laboratory guidelines for routine use.
- Open Access
- 1 January 2023
- Published by Acibadem Universitesi Saglik Bilimleri Dergisi in Acibadem Universitesi Saglik Bilimleri Dergisi
- Vol. 14 (1) , 1-9
Calculation of measurement uncertainty of 20 Clinical Chemistry Analytes according to the practical ISO approach
Purpose: Measurement Uncertainty (MU) is a valuable tool for evaluating analytical performance and interpreting results in clinical laboratories. The International Organization for Standardization (ISO) has proposed a practical approach for MU calculation in its ISO/TS 20914:2019 guide. This study aimed to calculate the MU values of 20 clinical chemistry analyses per the ISO guideline and compare them with the Maximum expanded allowable measurement uncertainty (MAU) values. Methods: The study was performed using 6-month internal quality control (IQC) values (uRw) and calibrator uncertainty (ucal) in line with the recommendations of the ISO/TS 20914:2019 guideline. The common MU value was calculated for 20 clinical chemistry tests on two identical devices, Roche Cobas 6000 c501 (Roche Diagnostics, Mannheim, Germany) analyzers. The calculated MU values for the tests were compared with the current MAU values in the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Biological Variation database (the current Clinical Laboratory Improvement Amendments/CLIA recommendation for Ethanol has been selected). Results: MU values for Alanine aminotransferase, C-reactive Protein, Iron, Ethanol, Total Bilirubin, Triglyceride, and Blood urea nitrogen remained within the MAU limits. The MU values of the other 13 tests (excluding Aspartate aminotransferase, Glucose, and Potassium Level 2 IQC) exceeded the MAU values. Conclusion: It was observed that the uRw value affected the MU value the most. Close monitoring and evaluation of uRw and thus IQC and implementation of corrective and preventive actions may reduce MU.
- 1 January 2023
- Published by Acibadem Universitesi Saglik Bilimleri Dergisi in Acibadem Universitesi Saglik Bilimleri Dergisi
- Vol. 14 (1) , 1-9
Open AccessCalculation of measurement uncertainty of 20 Clinical Chemistry Analytes according to the practical ISO approach
Purpose: Measurement Uncertainty (MU) is a valuable tool for evaluating analytical performance and interpreting results in clinical laboratories. The International Organization for Standardization (ISO) has proposed a practical approach for MU calculation in its ISO/TS 20914:2019 guide. This study aimed to calculate the MU values of 20 clinical chemistry analyses per the ISO guideline and compare them with the Maximum expanded allowable measurement uncertainty (MAU) values. Methods: The study was performed using 6-month internal quality control (IQC) values (uRw) and calibrator uncertainty (ucal) in line with the recommendations of the ISO/TS 20914:2019 guideline. The common MU value was calculated for 20 clinical chemistry tests on two identical devices, Roche Cobas 6000 c501 (Roche Diagnostics, Mannheim, Germany) analyzers. The calculated MU values for the tests were compared with the current MAU values in the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Biological Variation database (the current Clinical Laboratory Improvement Amendments/CLIA recommendation for Ethanol has been selected). Results: MU values for Alanine aminotransferase, C-reactive Protein, Iron, Ethanol, Total Bilirubin, Triglyceride, and Blood urea nitrogen remained within the MAU limits. The MU values of the other 13 tests (excluding Aspartate aminotransferase, Glucose, and Potassium Level 2 IQC) exceeded the MAU values. Conclusion: It was observed that the uRw value affected the MU value the most. Close monitoring and evaluation of uRw and thus IQC and implementation of corrective and preventive actions may reduce MU.
- Open Access
- 26 December 2022
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 3 (4) , 335-340
The C-reactive protein-to-albumin ratio predicts one-year mortality in living donor kidney transplantation
Aim: The aim of this study was is to evaluate the effectiveness of the preoperative CRP/albumin ratio on first year mortality after living donor kidney transplantation. Material and Method: This retrospective single-center study includes a total of living kidney transplant recipients’ data who were transplanted between 2011-2020 years. Thirty-six patients who died within the first year after kidney transplantation among 2143 living kidney transplant recipients were included in the study group. Patients who have similar comobordities like mortality group patients who survives than one year after living donor kidney transplantation were enrolled as control group. Results: First year mortality was 1.67% (36/2143) in ten years. Patients in the mortality group were older than the control group (53±13 vs 43±12, p=0.002). The median time spent on dialysis in the mortality group was longer than in the control group (13 months vs 1 month, p=0.029). The median CRP/albumin ratio was higher in the mortality group (2.77 vs 0.85, p=0.001). CRP and CRP/albumin ratio were determined as independent factors affecting mortality in the first year after living donor kidney transplantation as a result of multivariate Cox regression analysis (HR=1.040;95% CI, 1.011-1.069; p=0.004 vs HR=1.148 95% CI, 1.044-1.262; p=0.007, respectively). ROC analysis showed that the CRP/albumin ratio had the power to predict one-year mortality (AUC 0.650 95% CI 0.513-0.787, p=0.041). Kaplan-Meier survival analysis showed a statistically significant difference between the two groups in terms of the cut-off value for CRP/albumin ratio (1.52). Conclusion: This study shows that the CRP/albumin ratio can be used to predict mortality in the first year after living donor kidney transplantation.
- 26 December 2022
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 3 (4) , 335-340
Open AccessThe C-reactive protein-to-albumin ratio predicts one-year mortality in living donor kidney transplantation
Aim: The aim of this study was is to evaluate the effectiveness of the preoperative CRP/albumin ratio on first year mortality after living donor kidney transplantation. Material and Method: This retrospective single-center study includes a total of living kidney transplant recipients’ data who were transplanted between 2011-2020 years. Thirty-six patients who died within the first year after kidney transplantation among 2143 living kidney transplant recipients were included in the study group. Patients who have similar comobordities like mortality group patients who survives than one year after living donor kidney transplantation were enrolled as control group. Results: First year mortality was 1.67% (36/2143) in ten years. Patients in the mortality group were older than the control group (53±13 vs 43±12, p=0.002). The median time spent on dialysis in the mortality group was longer than in the control group (13 months vs 1 month, p=0.029). The median CRP/albumin ratio was higher in the mortality group (2.77 vs 0.85, p=0.001). CRP and CRP/albumin ratio were determined as independent factors affecting mortality in the first year after living donor kidney transplantation as a result of multivariate Cox regression analysis (HR=1.040;95% CI, 1.011-1.069; p=0.004 vs HR=1.148 95% CI, 1.044-1.262; p=0.007, respectively). ROC analysis showed that the CRP/albumin ratio had the power to predict one-year mortality (AUC 0.650 95% CI 0.513-0.787, p=0.041). Kaplan-Meier survival analysis showed a statistically significant difference between the two groups in terms of the cut-off value for CRP/albumin ratio (1.52). Conclusion: This study shows that the CRP/albumin ratio can be used to predict mortality in the first year after living donor kidney transplantation.
- 16 July 2022
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 158 (4) , 494-498
Negligible Specimen Hemolysis Is Observed With Sarstedt S-Monovette Coagulation Tubes in Aspiration Mode
Objectives: We aimed to compare the levels of hemolysis in the blood collected using the vacuum and aspiration modes via Sarstedt S-Monovette coagulation tubes. Methods: Forty volunteers were included in the study. Blood samples were collected using two different modes in the S-Monovette citrate tube (Sarstedt AG). Prothrombin time, active partial thromboplastin time, fibrinogen, and D-dimer analyses were performed using the STA-Compact-Max 3 analyzer (Stago). The hemolysis levels of the samples were measured by both Stago’s semiquantitative hemolysis index (H-index) module and the quantitative H-index measurement of the Roche cobas 6000 (Roche Diagnostics) analyzer. Results: Roche’s quantitative H-index values were statistically significantly lower in the aspiration mode. No clinically significant difference was observed between coagulation test results. Conclusions: Using the S-Monovette citrate tubes can reduce spurious hemolysis and improve patient safety.
- 16 July 2022
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 158 (4) , 494-498
Negligible Specimen Hemolysis Is Observed With Sarstedt S-Monovette Coagulation Tubes in Aspiration Mode
Objectives: We aimed to compare the levels of hemolysis in the blood collected using the vacuum and aspiration modes via Sarstedt S-Monovette coagulation tubes. Methods: Forty volunteers were included in the study. Blood samples were collected using two different modes in the S-Monovette citrate tube (Sarstedt AG). Prothrombin time, active partial thromboplastin time, fibrinogen, and D-dimer analyses were performed using the STA-Compact-Max 3 analyzer (Stago). The hemolysis levels of the samples were measured by both Stago’s semiquantitative hemolysis index (H-index) module and the quantitative H-index measurement of the Roche cobas 6000 (Roche Diagnostics) analyzer. Results: Roche’s quantitative H-index values were statistically significantly lower in the aspiration mode. No clinically significant difference was observed between coagulation test results. Conclusions: Using the S-Monovette citrate tubes can reduce spurious hemolysis and improve patient safety.
- 1 January 2022
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 68 (04/2022) , 817-823
Could S-Monovette Serum Gel Tubes be Used for Clinical Chemistry Analysis Instead of Serum Separator Tube II Advance?
Background: We aimed to compare the Sarstedt S-Monovette serum gel tube and the BD (Becton, Dickinson and Company) Serum Separator Tube II (SST II) Advance based on technical specifications and tests results. Methods: One hundred and twenty volunteers were included in the technical evaluation and 42 of 120 volunteers in the clinical evaluation. Blood was collected into S-Monovette, and SST II. Twelve quality indicators (QI) were determined for technical evaluation. For clinical evaluation, 29 clinical chemistry analytes were analysed simultaneously on a Roche Cobas 6000 c501 (Roche Diagnostics, Mannheim, Germany). Calculations were made using the formula suggested by the EFLM according to the QIs. If the difference between S-Monovette and SST II was < 1%, S-Monovette was considered sufficient for relevant QI. For clinical evaluation, Passing Bablok regression analysis and Bland-Altman plots were used. Desirable bias values for comparison with mean percentage difference (MPD) were obtained from biological variation databases. Results: S-Monovette tubes were found to be suitable for all QIs (difference < 1%). No significant differences were observed in analytes except lactate dehydrogenase (LDH). LDH results (U/L) obtained from the SST II were statistically significantly higher (SST II: 201 +/- 42, S-Monovette: 195 +/- 35, regression equation was y = 31.4 + 0.8x). The MPD of LDH (2.4%) remained within the desirable bias (3.4%); however, the 95% CI of the MPD of LDH (0.5% - 4.4%) exceeded the desirable bias. Conclusions: S-Monovette has been deemed appropriate for use in clinical chemistry analysis, as the MPD of LDH and other analytes remained within the bias limits. The LDH was considered sensitive to microhemolysis as a possible reason for the difference in LDH results.
- 1 January 2022
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 68 (04/2022) , 817-823
Could S-Monovette Serum Gel Tubes be Used for Clinical Chemistry Analysis Instead of Serum Separator Tube II Advance?
Background: We aimed to compare the Sarstedt S-Monovette serum gel tube and the BD (Becton, Dickinson and Company) Serum Separator Tube II (SST II) Advance based on technical specifications and tests results. Methods: One hundred and twenty volunteers were included in the technical evaluation and 42 of 120 volunteers in the clinical evaluation. Blood was collected into S-Monovette, and SST II. Twelve quality indicators (QI) were determined for technical evaluation. For clinical evaluation, 29 clinical chemistry analytes were analysed simultaneously on a Roche Cobas 6000 c501 (Roche Diagnostics, Mannheim, Germany). Calculations were made using the formula suggested by the EFLM according to the QIs. If the difference between S-Monovette and SST II was < 1%, S-Monovette was considered sufficient for relevant QI. For clinical evaluation, Passing Bablok regression analysis and Bland-Altman plots were used. Desirable bias values for comparison with mean percentage difference (MPD) were obtained from biological variation databases. Results: S-Monovette tubes were found to be suitable for all QIs (difference < 1%). No significant differences were observed in analytes except lactate dehydrogenase (LDH). LDH results (U/L) obtained from the SST II were statistically significantly higher (SST II: 201 +/- 42, S-Monovette: 195 +/- 35, regression equation was y = 31.4 + 0.8x). The MPD of LDH (2.4%) remained within the desirable bias (3.4%); however, the 95% CI of the MPD of LDH (0.5% - 4.4%) exceeded the desirable bias. Conclusions: S-Monovette has been deemed appropriate for use in clinical chemistry analysis, as the MPD of LDH and other analytes remained within the bias limits. The LDH was considered sensitive to microhemolysis as a possible reason for the difference in LDH results.
- Open Access
- 15 February 2021
- Published by Croatian Society for Medical Biochemistry and Laboratory Medicine in Biochemia Medica
- Vol. 31 (1) , 85-92
Effect of haemolysis on an enzymatic measurement of ethanol
Introduction: We investigated the interference of haemolysis on ethanol testing carried out with the Synchron assay kit using an AU680 autoanalyser (Beckman Coulter, Brea, USA). Materials and methods: Two tubes of plasma samples were collected from 20 volunteers. Mechanical haemolysis was performed in one tube, and no other intervention was performed in the other tube. After centrifugation, haemolysed and non-haemolysed samples were diluted to obtain samples with the desired free haemoglobin (Hb) values (0, 1, 2, 5, 10 g/L). A portion of these samples was then separated, and ethanol was added to the separated sample to obtain a concentration of 86.8 mmol/L ethanol. After that, these samples were diluted with ethanol-free samples with the same Hb concentration to obtain samples containing 43.4, 21.7, and 10.9 mmol/L. Each group was divided into 20 equal parts, and an ethanol test was carried out. The coefficient of variation (CV), bias, and total error (TE) values were calculated. Results: The TE values of haemolysis-free samples were approximately 2-5%, and the TE values of haemolysed samples were approximately 10- 18%. The bias values of haemolysed samples ranged from nearly - 6.2 to - 15.7%. Conclusions: Haemolysis led to negative interference in all samples. However, based on the 25% allowable total error value specified for ethanol in the Clinical Laboratory Improvement Amendments (CLIA 88) criteria, the TE values did not exceed 25%. Consequently, ethanol concentration can be measured in samples containing free Hb up to 10 g/L.
- 15 February 2021
- Published by Croatian Society for Medical Biochemistry and Laboratory Medicine in Biochemia Medica
- Vol. 31 (1) , 85-92
Open AccessEffect of haemolysis on an enzymatic measurement of ethanol
Introduction: We investigated the interference of haemolysis on ethanol testing carried out with the Synchron assay kit using an AU680 autoanalyser (Beckman Coulter, Brea, USA). Materials and methods: Two tubes of plasma samples were collected from 20 volunteers. Mechanical haemolysis was performed in one tube, and no other intervention was performed in the other tube. After centrifugation, haemolysed and non-haemolysed samples were diluted to obtain samples with the desired free haemoglobin (Hb) values (0, 1, 2, 5, 10 g/L). A portion of these samples was then separated, and ethanol was added to the separated sample to obtain a concentration of 86.8 mmol/L ethanol. After that, these samples were diluted with ethanol-free samples with the same Hb concentration to obtain samples containing 43.4, 21.7, and 10.9 mmol/L. Each group was divided into 20 equal parts, and an ethanol test was carried out. The coefficient of variation (CV), bias, and total error (TE) values were calculated. Results: The TE values of haemolysis-free samples were approximately 2-5%, and the TE values of haemolysed samples were approximately 10- 18%. The bias values of haemolysed samples ranged from nearly - 6.2 to - 15.7%. Conclusions: Haemolysis led to negative interference in all samples. However, based on the 25% allowable total error value specified for ethanol in the Clinical Laboratory Improvement Amendments (CLIA 88) criteria, the TE values did not exceed 25%. Consequently, ethanol concentration can be measured in samples containing free Hb up to 10 g/L.